孟鲁司特钠联合氨溴索治疗重症喘息性肺炎的疗效及安全性

Analysis of the efficacy and safety of montelukast sodium combined with ambroxol in treatment of severe asthmatic pneumonia

目的探讨孟鲁司特钠联合氨溴索治疗重症喘息性肺炎的效果及安全性。方法选取2013年1月至2015年12月湖南省永州市中心医院新收治入院且符合纳入标准的重症喘息性肺炎患儿98例,随机数字法随机分为对照组及治疗组,每组49例。对照组行常规的抗感染及对症治疗,治疗组在对照组的基础上联合使用孟鲁司特钠咀嚼片、氨溴索注射液雾化吸入,观察两组患儿咳嗽、喘息、气促、肺部湿啰音及哮鸣音等主要症状体征、住院天数、总有效率等情况。结果治疗组在气促、咳嗽、喘息、肺部湿罗音、肺部哮鸣音的持续时间及住院天数等方面均短于对照组,差异均有统计学意义(P均<0.01);治疗组的总有效率为97.96%,高于对照组的83.67%,治疗组的治疗效果明显优于对照组(P<0.05);两组均未出现药物不良反应。结论孟鲁司特钠联合氨溴索佐治重症喘息性肺炎安全有效,值得临床推广。

Objective To observe and analyze the curative effect of montelukast sodium combined with ambroxol in treating severe asthmatic pneumonia. Methods 98 cases of severe asthmatic pneumonia,who were admitted in Central Hospital of Yongzhou from January 2013 and December 2015 were randomly divided into the control group and the treatment group,49 cases in each group. Control group received conventional anti infection and symptomatic treatment;the treatment group received montelukast sodium chewable tablets and ambroxol atomization inhalation treatment in addition to the treatment of control group. The main symptoms and signs of two groups of children with cough,wheezing,anhelation,lung wet rales and wheezes singing sound,and hospitalization days,and efficiency were observed. Results The duration of treatment group with anhelation,cough,wheezing,lung wet rales,wheezing duration and hospitalization days was shorter than that of the control group,and the difference have statistical significance（All P〈0.01）;the total efficiency of treatment group was97.96% and the total efficiency of control group was 83.67%;the treatment effect of the treatment group is better than control group（P〈0.05）. Conclusion Montelukast sodium combined with ambroxol in treatment of severe asthmatic pneumonia is safe,effective,and worthy of promotion.